We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+25.95%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$269M
AUM Growth
-$59.3M
(-18%)
Cap. Flow
-$75.4M
Cap. Flow
% of AUM
-28.03%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
84
New
37
Increased
10
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$20.6M |
| 2 |
Medtronic
MDT
|
+$13.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$8.29M |
| 4 |
Legend Biotech
LEGN
|
+$7.63M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$7.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$17.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$17M |
| 4 |
ARK Innovation ETF
ARKK
|
+$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.05T
| $25.5M | 9.48% |
54,369
+9,921
| +22% | +$4.16M |
|
|
2
Johnson & Johnson
JNJ
$609B
| $21.1M | 7.83% |
+127,362
| New | +$20.6M |
|
|
AVDL
3
DELISTED
Avadel Pharmaceuticals
AVDL
| $17.1M | 6.37% |
1,039,474
-287,623
| -22% | -$3.74M |
|
4
West Pharmaceutical
WST
$25.3B
| $15.5M | 5.77% |
40,558
-26,272
| -39% | -$9.39M |
|
|
5
Regeneron Pharmaceuticals
REGN
$70.9B
| $14.8M | 5.51% |
20,644
-22,745
| -52% | -$17.5M |
|
6
Axsome Therapeutics
AXSM
$11.8B
| $14.4M | 5.34% |
200,080
+50,875
| +34% | +$3.75M |
|
|
7
Medtronic
MDT
$106B
| $14.2M | 5.26% |
+160,660
| New | +$13.8M |
|
|
RETA
8
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $9.82M | 3.65% |
96,274
+29,068
| +43% | +$2.75M |
|
|
CTLT
9
DELISTED
CATALENT, INC.
CTLT
| $8.72M | 3.24% |
200,997
-24,402
| -11% | -$1.07M |
|
|
10
Vertex Pharmaceuticals
VRTX
$123B
| $8.66M | 3.22% |
+24,597
| New | +$8.29M |
|
11
Teva Pharmaceuticals
TEVA
$37.3B
| $8.33M | 3.09% |
1,105,770
+93,397
| +9% | +$757K |
|
|
12
Legend Biotech
LEGN
$4.31B
| $8.06M | 3% |
+116,768
| New | +$7.63M |
|
13
X4 Pharmaceuticals
XFOR
$360M
| $7.95M | 2.96% |
136,665
+7,382
| +6% | +$379K |
|
14
Illumina
ILMN
$28.2B
| $7.66M | 2.85% |
41,975
-22,603
| -35% | -$4.58M |
|
15
DexCom
DXCM
$29.6B
| $6.66M | 2.47% |
+51,798
| New | +$6.26M |
|
|
NARI
16
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.6M | 2.45% |
+113,441
| New | +$7.16M |
|
|
SILK
17
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $6.45M | 2.4% |
+198,532
| New | +$7.25M |
|
18
Madrigal Pharmaceuticals
MDGL
$12.8B
| $6.01M | 2.23% |
26,010
+12,165
| +88% | +$3.29M |
|
19
Stevanato
STVN
$5.23B
| $5.71M | 2.12% |
176,359
-101,108
| -36% | -$2.84M |
|
|
IMGN
20
DELISTED
Immunogen Inc
IMGN
| $5.62M | 2.09% |
+297,807
| New | +$3.52M |
|
21
Praxis Precision Medicines
PRAX
$8.77B
| $5.62M | 2.09% |
325,641
+159,751
| +96% | +$2.45M |
|
22
Alnylam Pharmaceuticals
ALNY
$35.7B
| $5.6M | 2.08% |
+29,506
| New | +$5.85M |
|
|
ALPN
23
DELISTED
Alpine Immune Sciences Inc
ALPN
| $3.41M | 1.27% |
+331,992
| New | +$2.99M |
|
|
VRNA
24
DELISTED
Verona Pharma
VRNA
| $3.2M | 1.19% |
151,194
+53,380
| +55% | +$1.14M |
|
|
ETNB
25
DELISTED
89bio
ETNB
| $3.14M | 1.17% |
165,897
+8,672
| +6% | +$152K |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Tri Locum Partners held 84 positions worth $269M, down 18% from $328M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tri Locum Partners withdrew a net $75.4M in Q2 2023, closing 25 positions and reducing 12 holdings. Its most notable exit was Abbott, an estimated $17.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials and Industrials.
Against the trend, Tri Locum Partners opened a new position in Johnson & Johnson worth $21.1M.
- Tri Locum Partners's largest Q2 2023 buy was Johnson & Johnson: 127,362 shares worth $21.1M.
- Tri Locum Partners added most to Eli Lilly in Q2 2023, an estimated $4.16M increase.
- Tri Locum Partners's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $17.5M.
- Tri Locum Partners fully exited Abbott in Q2 2023, selling an estimated $17.7M.
- Tri Locum Partners's ten largest holdings make up 56% of its $269M portfolio in Q2 2023.
- Tri Locum Partners opened 37 new positions and closed 25 in Q2 2023.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $269M.
Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.